Cite
HARVARD Citation
Fontaniere, C. et al. (n.d.). 2095 Survival benefit, safety, and prognostic factors for outcome with Regorafenib (RE) in patients (pts) with pretreated metastatic colorectal cancer (mCRC). Main analyses of the REBECCA study. European journal of cancer. pp. S360-. [Online].